July 23, 2026
New Medical Product Launch Framework
Launch Plan Sign-Off Record — Version 3
| Reviewer | Status | Date |
|---|---|---|
| Darin Dixon - VP | Pending | — |
| Alicia Anselmo - Service Coordination Manager | Pending | — |
| Carlos Rangel - Service Manager | Pending | — |
| David Vincent III - Service Manager | Pending | — |
| Jean Aragundi - Service Manager | Pending | — |
| Mikulich Ryan - VP Sales | Pending | — |
| Gene Borbone - Service Operations Director | ✓ Approved | Jul 29, 2026 |
In Review
Awaiting approval — 1 of 7 reviewers have signed off.
Version 3
📋 Launch Plan Sign-offs
Darin Dixon - VP
Pending
Alicia Anselmo - Service Coordination Manager
Pending
Carlos Rangel - Service Manager
Pending
David Vincent III - Service Manager
Pending
Jean Aragundi - Service Manager
Pending
Mikulich Ryan - VP Sales
Pending
Gene Borbone - Service Operations Director
Approved
👥 Manage Launch Reviewers
Darin Dixon - VP (ID: 68)
Alicia Anselmo - Service Coordination Manager (ID: 54)
Carlos Rangel - Service Manager (ID: 25)
David Vincent III - Service Manager (ID: 231)
Jean Aragundi - Service Manager (ID: 1)
Mikulich Ryan - VP Sales (ID: 1029)
Gene Borbone - Service Operations Director (ID: 93)
🕘 Launch Version History — Editing Version 3
Version 2 — New Medical Product Launch Framework
Version 1 — APH550
Version 1 — New Medical Product Launch Framework
1.0 EXECUTIVE SUMMARY
No criteria logged for this section.
💡 Tip: Use 'Label -- Value' format for top metadata grid items (e.g. Target Launch Date -- Q3 2026). Use 'Heading | Content' for subtitles[cite: 1].
2.0 PRODUCT OVERVIEW
- Comprehensive technical specs, features, and mechanism of action.
- Clearly defined clinical uses, scope of treatment, and restrictions.
- Summary of supporting clinical trial data, peer-reviewed publications, and efficacy findings.
- FDA clearances (510k/PMA), CE Mark status, and post-market compliance requirements.
- Analysis of direct and indirect competitor solutions, strengths, and differentiators.
- Overview of issued patents, trademarks, and pending protection filings.
Detailed Product Description
Indications & Contraindications
Clinical Evidence
Regulatory Status
Competitive Landscape
Intellectual Property
3.0 TARGET AUDIENCE AND MARKET ANALYSIS
- Demographics, disease prevalence, and unmet therapeutic needs.
- Key specialties, prescribers, operators, and clinical personnel.
- Total Addressable Market (TAM), growth projections, and market drivers.
- Key subgroups requiring tailored positioning or specialty outreach.
- Prominent industry experts identified for advocacy and scientific advisory.
- Coverage policies, coding/billing considerations, and access barriers.
Target Patient Population
Target Healthcare Professionals (HCPs)
Market Size & Opportunity
Market Segmentation
Key Opinion Leaders (KOLs)
Payers & Reimbursement Landscape
4.0 LAUNCH STRATEGY AND PLAN
- Core marketing messaging tailored across distinct target personas.
- Direct sales force execution combined with authorized distribution partners.
- Rollout stages across priority geographic regions and clinical tier accounts.
- Sales team structures, quota targets, training certification, and logistics.
- Pre-launch awareness, launch events, PR outreach, and conference presence.
- Scientific engagement plans, investigator-initiated studies, and publication plans.
- Health economics research, value dossiers for payers, and formulary approvals.
- Digital campaign presence, web portals, social engagement, and EHR integration options.
- Comprehensive hands-on training programs, support routing, and complaint workflows.
Overall Positioning & Messaging
Go-to-Market Strategy
Phased Launch Approach
Sales & Distribution Strategy
Marketing & Communications
Medical Affairs Strategy
Market Access & HEOR
Digital Strategy
Customer Support & Training
5.0 LAUNCH TIMELINE AND MILESTONES
- Milestone tracking for regulatory approvals, inventory staging, and sales enablement.
- Execution timeline for initial commercial availability and announcement activities.
- Post-rollout growth monitoring, adoption reviews, and lifecycle expansion planning.
- Gantt chart mapping and cross-departmental deadline alignment.
Pre-Launch Phase
Launch Phase
Post-Launch Phase
Project Management Integration
6.0 BUDGET AND RESOURCES
- Expense breakdown across marketing, clinical, sales, regulatory, and logistics.
- Personnel staffing, equipment inventory, and operational tools required.
- Tracking target adoption, lead conversion, revenue, and unit placement.
- Financial forecasts, gross margin metrics, and break-even timelines.
Detailed Budget Allocation
Resource Allocation
Key Performance Indicators (KPIs)
ROI Projections
7.0 RISK ASSESSMENT AND MITIGATION
- Analysis of regulatory delays, supply chain disruptions, or competitive counter-strategies.
- Action plans and contingency procedures for identified high-impact risks.
- Ongoing risk review cadence and execution triggers for contingency plans.
Identification of Potential Risks
Mitigation Strategies
Monitoring & Trigger Protocols
8.0 TEAM AND RESPONSIBILITIES
- Cross-functional steering committee definition.
- Specific deliverables assigned across product, clinical, service, and marketing teams.
- Meeting cadence, status dashboards, and escalation channels.
Launch Team Structure
Roles & Responsibilities
Communication Plan
9.0 POST-LAUNCH EVALUATION
- Data collection protocols for ongoing performance reporting.
- Schedule for monthly/quarterly progress reviews and tactical pivots.
- Systematic survey collection from clinicians, field service, and sales reps.
- Ongoing product enhancements, software updates, and line extension roadmaps.
KPI Tracking & Metrics Cadence
Regular Review Meetings
Feedback Collection
Lifecycle Management
10.0 APPENDICES
- Market Research Studies & Clinical Summaries
- Regulatory Approval Files & Clearance Documentation
- Reimbursement Dossiers & Coding Guidance Sheets
- Sales & Service Technical Training Decks